Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, and currently in Phase 2 and Phase 3 clinical trials
This mechanism was elucidated by McCoy et al
Mechanism: Increased satiety signalling Delayed gastric emptying Reduced caloric intake It does not directly influence glucagon-mediated energy output
Here is what participants achieved at 72 weeks: To put that in perspective: someone starting at 250 pounds could lose between 37 and 52 pounds over roughly 18 months
US$ 24.05
US$ 24.73
US$ 26.05
US$ 28.74
US$ 25.85
US$ 26.03
